The tweet was deleted by the author.
But we saved everything 🙂.
Actinium Pharmaceuticals announced that an abstract on its Actimab-A therapy has been accepted for a poster presentation at ASH26. The research addresses the long-term safety and tolerability of Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (AML).
The poster will provide clinical insights into the use of Actimab-A in combination therapies for difficult-to-treat AML cases.
View post on X Loading...
Actinium Pharmaceuticals has recently presented preclinical data on ATNM-400 in lung, colorectal, and ovarian cancer models at EANM26 in Vienna. The company also delivered updates on ATNM-400 clinical and preclinical research in major cancer indications in a separate oncology research report. These activities reflect an ongoing focus on advancing targeted therapies for cancer.